- Regular use of aspirin and COX-2 inhibitors was associated with significant decreases in breast cancer risk among women with familial or genetic risk.
Why this matters
- Associations were not modified by familial or genetic risk, suggesting that regular aspirin and COX-2 inhibitor use may have an even greater benefit for those at higher risk.
- Prospective cohort of 5606 women with no history of breast cancer and combined retrospective+prospective cohort of 8233 women with and without a history of breast cancer.
- Funding: USA National Cancer Institute; others.
- Regular aspirin use was associated with decreased breast cancer risk in the combined cohort (HR, 0.63; 95% CI, 0.57-0.71), but did not achieve statistical significance in the prospective cohort (HR, 0.61; 95% CI, 0.33-1.14).
- Regular COX-2 inhibitor use was associated with a significant decrease in breast cancer risk in both the prospective (HR, 0.39; 95% CI, 0.15-0.97) and combined (HR, 0.29; 95% CI, 0.23-0.38) cohorts.
- Associations were similar when stratified by women not known to be mutation carriers and those with BRCA1 and BRCA2, as well as by estrogen receptor status and attained age.
- No association with use of other NSAIDs or acetaminophen.
- No data on dosage and only limited data on duration of use.